Health State Utilities of Patients with Heart Failure: A Systematic Literature Review

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background and Objectives

New treatments and interventions are in development to address clinical needs in heart failure. To support decision making on reimbursement, cost-effectiveness analyses are frequently required. A systematic literature review was conducted to identify and summarize heart failure utility values for use in economic evaluations.

Methods

Databases were searched for articles published until June 2019 that reported health utility values for patients with heart failure. Publications were reviewed with specific attention to study design; reported values were categorized according to the health states, ‘chronic heart failure’, ‘hospitalized’, and ‘other acute heart failure’. Interquartile limits (25th percentile ‘Q1’, 75th percentile ‘Q3’) were calculated for health states and heart failure subgroups where there were sufficient data.

Results

The systematic literature review identified 161 publications based on data from 142 studies. Utility values for chronic heart failure were reported by 128 publications; 39 publications published values for hospitalized and three for other acute heart failure. There was substantial heterogeneity in the specifics of the study populations, methods of elicitation, and summary statistics, which is reflected in the wide range of utility values reported. EQ-5D was the most used instrument; the interquartile limit for mean EQ-5D values for chronic heart failure was 0.64–0.72.

Conclusions

There is a wealth of published utility values for heart failure to support economic evaluations. Data are heterogenous owing to specificities of the study population and methodology of utility value elicitation and analysis. Choice of value(s) to support economic models must be carefully justified to ensure a robust economic analysis.

Electronic supplementary material

The online version of this article (10.1007/s40273-020-00984-6) contains supplementary material, which is available to authorized users.

Related collections

Most cited references 94

Record: found
Abstract: not found
Article: not found

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Piotr Ponikowski, Adriaan A. Voors, Stefan D. Anker … (2016)

0 comments Cited 2862 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

David Moher, Alessandro Liberati, Jennifer Tetzlaff … (2009)

0 comments Cited 1936 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Yuan-Pang Wang, Maheswar Satpathy, Mathilde Touvier … (2018)

Summary Background As mortality rates decline, life expectancy increases, and populations age, non-fatal outcomes of diseases and injuries are becoming a larger component of the global burden of disease. The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016. Methods We estimated prevalence and incidence for 328 diseases and injuries and 2982 sequelae, their non-fatal consequences. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between incidence, prevalence, remission, and cause of death rates for each condition. For some causes, we used alternative modelling strategies if incidence or prevalence needed to be derived from other data. YLDs were estimated as the product of prevalence and a disability weight for all mutually exclusive sequelae, corrected for comorbidity and aggregated to cause level. We updated the Socio-demographic Index (SDI), a summary indicator of income per capita, years of schooling, and total fertility rate. GBD 2016 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER). Findings Globally, low back pain, migraine, age-related and other hearing loss, iron-deficiency anaemia, and major depressive disorder were the five leading causes of YLDs in 2016, contributing 57·6 million (95% uncertainty interval [UI] 40·8–75·9 million [7·2%, 6·0–8·3]), 45·1 million (29·0–62·8 million [5·6%, 4·0–7·2]), 36·3 million (25·3–50·9 million [4·5%, 3·8–5·3]), 34·7 million (23·0–49·6 million [4·3%, 3·5–5·2]), and 34·1 million (23·5–46·0 million [4·2%, 3·2–5·3]) of total YLDs, respectively. Age-standardised rates of YLDs for all causes combined decreased between 1990 and 2016 by 2·7% (95% UI 2·3–3·1). Despite mostly stagnant age-standardised rates, the absolute number of YLDs from non-communicable diseases has been growing rapidly across all SDI quintiles, partly because of population growth, but also the ageing of populations. The largest absolute increases in total numbers of YLDs globally were between the ages of 40 and 69 years. Age-standardised YLD rates for all conditions combined were 10·4% (95% UI 9·0–11·8) higher in women than in men. Iron-deficiency anaemia, migraine, Alzheimer’s disease and other dementias, major depressive disorder, anxiety, and all musculoskeletal disorders apart from gout were the main conditions contributing to higher YLD rates in women. Men had higher age-standardised rates of substance use disorders, diabetes, cardiovascular diseases, cancers, and all injuries apart from sexual violence. Globally, we noted much less geographical variation in disability than has been documented for premature mortality. In 2016, there was a less than two times difference in age-standardised YLD rates for all causes between the location with the lowest rate (China, 9201 YLDs per 100 000, 95% UI 6862–11943) and highest rate (Yemen, 14 774 YLDs per 100 000, 11 018–19 228). Interpretation The decrease in death rates since 1990 for most causes has not been matched by a similar decline in age-standardised YLD rates. For many large causes, YLD rates have either been stagnant or have increased for some causes, such as diabetes. As populations are ageing, and the prevalence of disabling disease generally increases steeply with age, health systems will face increasing demand for services that are generally costlier than the interventions that have led to declines in mortality in childhood or for the major causes of mortality in adults. Up-to-date information about the trends of disease and how this varies between countries is essential to plan for an adequate health-system response.

0 comments Cited 1866 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Gian Luca Di Tanna:

ORCID: http://orcid.org/0000-0002-5470-3567

gditanna@georgeinstitute.org.au

Journal

Journal ID (nlm-ta): Pharmacoeconomics

Journal ID (iso-abbrev): Pharmacoeconomics

Title: Pharmacoeconomics

Publisher: Springer International Publishing (Cham )

ISSN (Print): 1170-7690

ISSN (Electronic): 1179-2027

Publication date (Electronic): 30 November 2020

Publication date PMC-release: 30 November 2020

Publication date (Print): 2021

Volume: 39

Issue: 2

Pages: 211-229

Affiliations

[1 ]GRID grid.1005.4, ISNI 0000 0004 4902 0432, Statistics Division, The George Institute for Global Health, Faculty of Medicine, , University of New South Wales, ; Sydney, NSW Australia

[2 ]GRID grid.476152.3, ISNI 0000 0004 0476 2707, Amgen (Europe) GmbH, Global Value & Access, Modeling Center of Excellence, ; Rotkreuz, Switzerland

[3 ]GRID grid.417886.4, ISNI 0000 0001 0657 5612, Amgen Inc, Global Health Economics, ; Thousand Oaks, CA USA

[4 ]Pharmerit - an OPEN Health company, Rotterdam, The Netherlands

[5 ]Pharmerit - an OPEN Health company, York, UK

[6 ]GRID grid.11835.3e, ISNI 0000 0004 1936 9262, Health Economics and Decision Science, University of Sheffield, ; Sheffield, UK

[7 ]GRID grid.415508.d, ISNI 0000 0001 1964 6010, The George Institute for Global Health, ; Level 5, 1 King St, Newtown, NSW 2042 Australia

Author information

Gian Luca Di Tanna http://orcid.org/0000-0002-5470-3567

Article

Publisher ID: 984

DOI: 10.1007/s40273-020-00984-6

PMC ID: 7867520

PubMed ID: 33251572

SO-VID: c3c746cf-9dc6-4e79-8c68-33de7beef675

License:

Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

History

Date accepted : 10 November 2020

Funding

Funded by: FundRef http://dx.doi.org/10.13039/100002429, Amgen;

Custom metadata

ScienceOpen disciplines: Economics of health & social care

Data availability:

ScienceOpen disciplines: Economics of health & social care

Comments

Comment on this article

scite_

Cited by 11

See all cited by

Most referenced authors 12,887

See all reference authors

Health State Utilities of Patients with Heart Failure: A Systematic Literature Review

Read this article at

Abstract

Background and Objectives

Methods

Results

Conclusions

Electronic supplementary material

Related collections

AboutScience

Most cited references 94

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Author and article information

Contributors

Journal

Affiliations

Author information

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 256

Cited by 11

Most referenced authors 12,887